SpiD3 treatment of TNFα stimulated CLL cells resulted in marked inhibition of p65 (canonical) and RELB (noncanonical) nuclear translocation, whereas TPCA-1 (control NFκB inhibitor) only blocked p65 nuclear translocation (Supplementary Fig. S6A). Here, TNF is linked to B-cell chronic lymphocytic leukemia.